G49N Stock Overview
A clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 4 more risks
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.28 |
| 52 Week High | €0.55 |
| 52 Week Low | €0.24 |
| Beta | 2.33 |
| 11 Month Change | 1.28% |
| 3 Month Change | -14.62% |
| 1 Year Change | -39.67% |
| 33 Year Change | -95.20% |
| 5 Year Change | -75.40% |
| Change since IPO | -96.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| G49N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.2% | -0.7% | -0.02% |
| 1Y | -39.7% | -17.2% | 8.2% |
Return vs Industry: G49N underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: G49N underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| G49N volatility | |
|---|---|
| G49N Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G49N's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G49N's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| G49N fundamental statistics | |
|---|---|
| Market cap | €36.28m |
| Earnings (TTM) | -€20.11m |
| Revenue (TTM) | €1.98m |
18.4x
P/S Ratio-1.8x
P/E RatioIs G49N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G49N income statement (TTM) | |
|---|---|
| Revenue | €1.98m |
| Cost of Revenue | €0 |
| Gross Profit | €1.98m |
| Other Expenses | €22.08m |
| Earnings | -€20.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 23, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,017.51% |
| Debt/Equity Ratio | -85.5% |
How did G49N perform over the long term?
See historical performance and comparison